XOMA Ltd., announces advances in neutralizing botulinum neurotoxin Type A

XOMA Ltd. has announced results that demonstrate its monoclonal antibody technology XOMA 3AB's ability to neutralize botulinum neurotoxin Type A, a bioterror threat that causes paralysis.

One single antibody is often not effective in neutralizing a botulism as well as many other infectious diseases, especially in cases where multiple strains or subtypes exist. XOMA's technology combats this by co-formulating and delivering multiple antibodies in a single injectable solution, potentially increasing efficacy for infectious and other diseases.

XOMA 3AB consists of three human antibodies that bind to unique epitopes on the botulinum A toxin. In composite, the antibodies have shown to have unprecedented potency against the toxin. XOMA 3AB is being developed under existing research contracts with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health.

"These results highlight the breadth of XOMA's advanced expertise in antibody development, optimization and formulation," Patrick J. Scannon, M.D., Ph.D., and executive vice president and chief medical officer of Xoma, said. "We are utilizing multiple technologies to provide stable products with longer shelf lives and lower costs than third generation biologics. For the first time, we have also solved a key quality problem in ensuring the mix and potency of multiple antibodies. Specialized assays were developed and implemented to ensure precise characterization, stability and release of this multiple antibody cocktail."

Organizations in this story

National Institutes of Health 9000 Rockville Pike Bethesda, MD 20892

Get notified the next time we write about National Institutes of Health!